NCT01552681终止2 期
A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Baminercept, a Lymphotoxin-beta Receptor Fusion Protein, for the Treatment of Primary Sjögren's Syndrome (ASJ02)
National Institute of Allergy and Infectious Diseases (NIAID)18 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2012年7月最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 52
- 试验地点
- 18
- 主要终点
- Change From Screening in Stimulated Whole Salivary Flow at Week 24
研究概览
简要总结
The purpose of the study is to find out if the experimental study agent, baminercept, is effective in treating patients with Sjögren's syndrome. The study will also determine if the study agent can be safely given to patients with Sjögren's syndrome; examine how it affects symptoms of the disease; and attempt to understand how baminercept affects the underlying mechanisms of Sjögren's syndrome and the immune system.
详细描述
Sjögren's syndrome is an autoimmune disorder in which a person's own immune cells attack the body's tear and salivary glands. This disease is the second most common autoimmune disorder, affects close to four million people in the U.S., and has no known cause. About one-third of patients with Sjögren's syndrome have enlarged parotid glands (the largest salivary glands, the glands that make saliva); inflammation of organs such as the lungs and joints may also occur. There is no known effective treatment other than measures that can relieve symptoms. One of the most bothersome symptoms is dryness of the eyes and mouth. Eye drops and saliva stimulants (which help make more saliva) are common treatments. When other organs are affected, symptoms are treated with corticosteroids (prednisone), non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen and naproxen), hydroxychloroquine (Plaquenil®) or other medications that suppress the immune system. These drugs may curb or kill cells of the immune system, but they are not always helpful, do not cure Sjögren's syndrome, and can have many side effects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Has provided written informed consent;
- •Between the ages of 18-75 years (inclusive);
- •Body weight ≥ 40 kg;
- •Meets the revised European criteria proposed by the American-European Consensus Group for primary Sjögren's Syndrome at screening. These criteria include 3 of the following 4 items:
- •ocular symptoms;
- •oral symptoms;
- •Schirmer's I test showing less than 6 mm of wetting per five minutes in at least one eye, or filamentary keratitis on slit lamp examination, or positive lissamine green staining; or
- •diminished salivary production (unstimulated whole salivary flow rate ≤ 1.5 mL/15 min); PLUS, either:
- •a positive test for serum SS-A and/or SS-B antibodies, or
- •focal lymphocytic sialadenitis, with a focus score ≥ 1.0 per 4 millimeters ^2(mm^2) on minor salivary biopsy.
- •Stimulated salivary flow of ≥ 0.1 mL/minute (min) (at screening);
- •Has one or more of the following systemic manifestations of Sjögren's Syndrome that are not life-threatening:
- •fatigue (as measured by > 50 mm on a 100 mm VAS);
- •joint pain (as measured by > 50 mm on a 100 mm VAS);
- •peripheral neuropathy (documented by nerve conduction velocity study);
- •interstitial lung disease (documented by radiography and/or altered pulmonary function tests;
- •leukocytoclastic vasculitis;
- •renal tubular acidosis;
- •interstitial nephritis;
- •severe parotid swelling;
- •other extraglandular manifestations causing organ system dysfunction.
- •If taking prednisone (or equivalent corticosteroid), the dose must be ≤ 10 mg/day and stable for at least 4 weeks prior to Screening;
- •If taking hydroxychloroquine, the dose must be stable for at least 12 weeks prior to Screening;
- •If taking a cholinergic stimulant (e.g. pilocarpine, cevimeline), the dose must be stable for at least 4 weeks prior to Screening;
- •Subjects must agree not to become pregnant or to impregnate a female. Because of the risk involved, participants and their partners (if of reproductive potential) must use two methods of birth control. They must continue to use both methods until 6 months after stopping study drug. Two of the birth control methods listed below may be chosen:
- •Hormonal contraception;
- •Male or female condoms with or without spermicide;
- •Diaphragm or cervical cap with a spermicide;
- •Intrauterine device (IUD).
排除标准
- •Has an active infection excluding superficial cutaneous fungal or viral infections;
- •Has a chronic or persistent infection that might be worsened by immunosuppressive treatment (e.g., human immunodeficiency virus [HIV], hepatitis B, hepatitis C, or tuberculosis);
- •History of TB or positive intradermal skin test for purified protein derivative (PPD); positive Mantoux test defined as 10 mm of induration (size of raised bump, not redness), or equivalent positive TB test result, as per country clinical standards, during the screening period. Subjects whose PPD induration is ≥ 5 mm but < 10 mm are eligible for the study if they had a negative chest x-ray during the screening period. There must be no other clinical evidence of TB on physical examination of the subject. Note: Subjects who have had prior adequate prophylaxis treatment for latent TB with an appropriate course of isoniazid or equivalent, per country standards, are not excluded from study participation. PPD should not be administered within 6 weeks of a live-virus vaccine;
- •History of recurrent significant infections or occurrence of a serious local infection (e.g., cellulitis, abscess) or systemic infection (e.g., pneumonia, septicemia) within twelve weeks prior to Day 0;
- •Receipt of live vaccine within six weeks prior to Day 0;
- •History or presence of primary or secondary immunodeficiency;
- •History of any life-threatening allergic reactions;
- •Is a pregnant or nursing female;
- •Ongoing anticoagulant therapy, which is a contraindication for labial salivary biopsy or tonsil biopsy;
- •Concurrent use of anticholinergic agents, such as tricyclic antidepressants, antihistamines, phenothiazines, antiparkinsonian drugs, anti-asthmatic medications, or gastrointestinal (GI) medications that cause xerostomia in more than 10% of patients;
- •Treatment with any of the following within the defined period prior to Screening:
- •2 years for rituximab;
- •24 weeks for cyclophosphamide;
- •8 weeks for azathioprine, cyclosporine, methotrexate, or mycophenolate mofetil;
- •4 weeks for intravenous immunoglobulin;
- •4 weeks for etanercept;
- •8 weeks for adalimumab;
- •12 weeks for infliximab.
- •Prednisone (or equivalent corticosteroid) > 10 mg/day;
- •A definite diagnosis of RA, SLE, systemic sclerosis, or dermatomyositis;
- •A history of alcohol or substance abuse within 12 months of the screening visit;
- •A history of head and neck radiation therapy, sarcoidosis, or graft-versus-host disease;
- •A history of malignancy, except for a resected basal or major squamous cell carcinoma, cervical dysplasia, or in situ cervical cancer Grade I, within the last five years;
- •Severe pulmonary disease as manifested by one of the following at Screening:
- •Resting oxygen saturation < 92%;
- •Force vital capacity (FVC) < 50% predicted;
- •Diffusion lung capacity for carbon monoxide (DLCO) < 50%;
- •Abnormal laboratory results for the following parameters at the screening visit:
- •Absolute neutrophil count (ANC): < 1,500/mm^3;
- •Platelets: < 100,000/mm^3;
- •Hemoglobin: < 9 grams (g)/deciliter (dL);
- •Serum creatinine: ≥ 2.0 mg/dL;
- •AST: > 1.5x upper limit of normal, or
- •ALT: > 1.5x upper limit of normal.
- •A psychiatric disorder rendering the subject incapable of providing informed consent;
- •Plans for foreign travel to countries other than Canada or Western Europe within the treatment period;
- •Inability or unwillingness to follow the protocol;
- •Any condition or treatment that, in the opinion of the investigator, places the subject at an unacceptable risk as a participant in the trial;
- •Rochester substudy subjects who meet the following criteria are disqualified from enrolling in the tonsil biopsy substudy if they:
- •Have any side effects to local anesthetics (e.g., lidocaine);
- •Have any side effects to silver nitrate;
- •Do not have tonsils;
- •Are not able to go 48 hours without any NSAIDS;
- •Are not able to go 2 weeks without acetylsalicylic acid (aspirin).
研究组 & 干预措施
Baminercept
Experimental
Subcutaneous injections of 100 mg every week for 24 weeks
干预措施: Baminercept (Biological)
Placebo
Placebo Comparator
Subcutaneous injections of matched placebo every week for 24 weeks
干预措施: Placebo (Other)
结局指标
主要结局
Change From Screening in Stimulated Whole Salivary Flow at Week 24
时间窗: Screening to Week 24
After an unstimulated salivary flow assessment the participant was administered a single 5-mg dose of pilocarpine to stimulate saliva production. One hour after the administration of pilocarpine the participant spit into a preweighed 50-cm centrifuge tube for 15 minutes. The sample was weighed to determine the volume (1 g = 1 mL) of saliva. The volume of saliva (mL) was divided by the duration of the test (minutes) to calculate the stimulated salivary flow rate (mL/min). Change from screening was computed as the value at Week 24 minus the screening value. A positive value in change from screening indicates an improvement and a negative value indicates worsening.
次要结局
- Change From Screening in Stimulated Whole Salivary Flow at Week 48(Screening to Week 48)
- Change From Screening in Unstimulated Whole Salivary Flow at Week 24(Screening to Week 24)
- Change From Screening in Unstimulated Whole Salivary Flow at Week 48(Screening to Week 48)
- Change From Baseline in European League Against Rheumatism (EULAR) Sjogren's Syndrome Disease Activity Index (ESSDAI) at Week 24(Baseline to Week 24)
- Percent of Subjects Classified as Responders According to the Patient Self-Assessment of Fatigue, Overall Dryness, and Joint Pain at Week 24(Week 24)
- Percent of Subjects Classified as Responders According to the Patient Self-Assessment of Fatigue, Overall Dryness, and Joint Pain at Week 48(Week 48)
- Change From Baseline in Visual Analog Scale (VAS) Scores for Sjogren's Syndrome Symptom Survey at Week 24(Week 24)
- Change From Baseline in Visual Analog Scale (VAS) Scores for Sjogren's Syndrome Symptom Survey at Week 48(Week 48)
- Change From Baseline in Patient Self-Assessment of Fatigue, Overall Dryness, and Joint Pain at Week 24(Week 24)
- Change From Baseline in Patient Self-Assessment of Fatigue, Overall Dryness, and Joint Pain at Week 48(Week 48)
- Change From Baseline in Patient and Physician Global Assessments of Disease Activity at Week 24(Week 24)
- Change From Baseline in Patient and Physician Global Assessments of Disease Activity at Week 48(Week 48)
- Change From Baseline in Tear Secretion as Measured by Schirmer's I Test at Week 24(Week 24)
- Change From Baseline in Tear Secretion as Measured by Schirmer's I Test at Week 48(Week 48)
- Change From Baseline in Tear Secretion as Measured by Lissamine Green Staining at Week 24(Week 24)
- Change From Baseline in Tear Secretion as Measured by Lissamine Green Staining at Week 48(Week 48)
- Change From Baseline in the Short Form 36 (SF-36) Physical and Mental Health Component Summary Scores (PCS and MCS) at Week 24(Week 24)
- Change From Baseline in the Short Form 36 (SF-36) Physical and Mental Health Component Summary Scores (PCS and MCS) at Week 48(Week 48)
- Percent of Participants With Adverse Events of Grade 3 or Higher(From the time of administration of the first dose of study drug until the participant completed study participation, an average of 48 weeks.)
- Percent of Participants With Grade 3 or Higher Infection Adverse Event(From the time of administration of the first dose of study drug until the participant completed study participation, an average of 48 weeks.)
- Percent of Participants With Injection Site Reaction or Any Grade 2 or Higher Adverse Event Within 24 Hours of Injection(From the time of administration of the first dose of study drug until the participant completed study participation, an average of 48 weeks.)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
2 期
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusNCT02708095Eli Lilly and Company314
已完成
2 期
Efficacy And Safety Of GW642444M Comparing Placebo In Adolescent And Adult Subjects With Persistent Asthma.AsthmaNCT00600171GlaxoSmithKline614
已完成
3 期
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)Systemic Lupus ErythematosusNCT03616964Eli Lilly and Company778
终止
3 期
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT03616912Eli Lilly and Company830
已完成
2 期
A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Persistent Asthma.AsthmaNCT00398645GlaxoSmithKline648